1. Scrip
  2. >>Business
  3. >>Deals

What Korean Biopharma Firms Need To Consider Before Deal Negotiations

Licensing Deals Falling, But Firms Actively Moving

 
• By Jung Won Shin

A report by Korea Bio-Economy Research Center outlines key factors that could help ensure successful licensing deal negotiations for Korean biopharmas.

dealmaking
Bioventure License Deal Performance Increasingly Assessed During IPO Filings • Source: Shutterstock

Given the current weak mergers and acquisitions activity in the Korean bioventure industry, any rewards from investment in the sector will largely come from initial public offerings, although this may not be the ultimate goals for these companies. 

As such, their out-licensing deal performance is increasingly seen as a way to measure market competitiveness of their technology by the Korea Exchange in assessing IPO filings,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Business